奈必洛尔对接受蒽环类药物治疗患者的心脏保护作用：一项随机安慰剂对照试验。 - Suppr

Cardioprotection with nebivolol in patients undergoing anthracyclines: a randomized placebo-controlled trial.

作者信息

Stefanini Giulio, Carlo-Stella Carmelo, Cannata Francesco, Chiarito Mauro, Figliozzi Stefano, Novelli Laura, Lisi Costanza, Bombace Sara, Catapano Federica, Indolfi Eleonora, Panico Cristina, Corrado Francesco, Masci Giovanna, Mazza Rita, Ricci Francesca, Monti Lorenzo, Ferrante Giuseppe, Reimers Bernhard, Santoro Armando, Francone Marco, da Costa Bruno R, Jüni Peter, Condorelli Gianluigi

机构信息

Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20090 Pieve Emanuele-Milan, Italy.

IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089 Rozzano-Milan, Italy.

出版信息

Cardiovasc Res. 2025 Apr 22;121(2):227-229. doi: 10.1093/cvr/cvae266.

DOI:10.1093/cvr/cvae266

PMID:39842858

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12012441/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c4dd/12012441/21827ce0ef0b/cvae266f1.jpg

相似文献

Cardioprotection with nebivolol in patients undergoing anthracyclines: a randomized placebo-controlled trial.奈必洛尔对接受蒽环类药物治疗患者的心脏保护作用：一项随机安慰剂对照试验。

Cardiovasc Res. 2025 Apr 22;121(2):227-229. doi: 10.1093/cvr/cvae266.

Nebivolol versus placebo in patients undergoing anthracyclines (CONTROL Trial): rationale and study design.比索洛尔与安慰剂在接受蒽环类药物治疗的患者中的比较（CONTROL 试验）：原理和研究设计。

J Cardiovasc Med (Hagerstown). 2023 Jul 1;24(7):469-474. doi: 10.2459/JCM.0000000000001491.

Placebo effect and efficacy of nebivolol in patients with hypertension not controlled with lisinopril or losartan: a phase IV, randomized, placebo-controlled trial.安慰剂效应及比索洛尔在未被依那普利或氯沙坦控制的高血压患者中的疗效：一项 IV 期、随机、安慰剂对照试验。

Am J Cardiovasc Drugs. 2013 Apr;13(2):129-40. doi: 10.1007/s40256-013-0010-y.

Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study.比索洛尔对蒽环类药物诱导性心肌病的保护作用：一项随机对照研究。

Int J Cardiol. 2013 Sep 1;167(5):2306-10. doi: 10.1016/j.ijcard.2012.06.023. Epub 2012 Jun 22.

Efficacy and tolerability of nebivolol monotherapy by baseline systolic blood pressure: a retrospective analysis of pooled data from two multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging studies in patients with mild to moderate essential hypertension.根据基线收缩压评估比索洛尔单药治疗的疗效和耐受性：两项多中心、12 周、随机、双盲、安慰剂对照、平行分组、剂量范围研究的汇总数据的回顾性分析，这些研究纳入了轻至中度原发性高血压患者。

Clin Ther. 2009 Sep;31(9):1946-56. doi: 10.1016/j.clinthera.2009.08.028.

Efficacy and tolerability of nebivolol: does age matter? A retrospective analysis of three randomized, placebo-controlled trials in stage I-II hypertension.奈必洛尔的疗效与耐受性：年龄有影响吗？一项针对I-II期高血压的三项随机、安慰剂对照试验的回顾性分析。

Ther Adv Cardiovasc Dis. 2012 Oct;6(5):185-99. doi: 10.1177/1753944712459593. Epub 2012 Sep 24.

Nebivolol monotherapy in younger adults (younger than 55 years) with hypertension: a randomized, placebo-controlled trial.比索洛尔单药治疗年轻成年人（<55 岁）高血压：一项随机、安慰剂对照试验。

J Clin Hypertens (Greenwich). 2013 Sep;15(9):687-93. doi: 10.1111/jch.12169. Epub 2013 Jul 16.

Efficacy and tolerability of nebivolol in stage I-II hypertension: a pooled analysis of data from three randomized, placebo-controlled monotherapy trials.在 I-II 期高血压中，奈必洛尔的疗效和耐受性：来自三项随机、安慰剂对照单药治疗试验数据的汇总分析。

Clin Ther. 2011 Sep;33(9):1150-61. doi: 10.1016/j.clinthera.2011.07.020. Epub 2011 Aug 24.

Treatment of ambulatory hypertensives with nebivolol or hydrochlorothiazide alone and in combination. A randomized, double-blind, placebo-controlled, factorial-design trial.

Am J Hypertens. 1994 Feb;7(2):137-45. doi: 10.1093/ajh/7.2.137.

A randomized, double-blind, placebo-controlled parallel-group study to assess the efficacy and safety of nebivolol, a novel beta-blocker, in patients with mild to moderate hypertension.一项随机、双盲、安慰剂对照平行组研究，旨在评估新型β受体阻滞剂奈必洛尔治疗轻至中度高血压患者的疗效和安全性。

J Clin Hypertens (Greenwich). 2007 Sep;9(9):667-76. doi: 10.1111/j.1524-6175.2007.06679.x.

本文引用的文献

J Cardiovasc Med (Hagerstown). 2023 Jul 1;24(7):469-474. doi: 10.2459/JCM.0000000000001491.

Efficacy and safety of cardioprotective drugs in chemotherapy-induced cardiotoxicity: an updated systematic review & network meta-analysis.心脏保护药物在化疗所致心脏毒性中的疗效与安全性：一项更新的系统评价与网状Meta分析

Cardiooncology. 2023 Feb 18;9(1):10. doi: 10.1186/s40959-023-00159-0.

2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).2022年欧洲心脏病学会（ESC）与欧洲血液学协会（EHA）、欧洲治疗放射学与肿瘤学协会（ESTRO）以及国际心脏肿瘤学会（IC-OS）合作制定的心脏肿瘤学指南。

Eur Heart J. 2022 Nov 1;43(41):4229-4361. doi: 10.1093/eurheartj/ehac244.

The Role of Cardioprotection in Cancer Therapy Cardiotoxicity: State-of-the-Art Review.心脏保护在癌症治疗中的作用：心脏毒性——最新综述

JACC CardioOncol. 2022 Mar 15;4(1):19-37. doi: 10.1016/j.jaccao.2022.01.101. eCollection 2022 Mar.

Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA): Extended Follow-Up of a 2×2 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol.辅助乳腺癌治疗中心肌功能障碍的预防（PRADA）：坎地沙坦和倍他洛尔 2×2 析因、随机、安慰剂对照、双盲临床试验的延长随访。

Circulation. 2021 Jun 22;143(25):2431-2440. doi: 10.1161/CIRCULATIONAHA.121.054698. Epub 2021 May 16.

Efficacy of Neurohormonal Therapies in Preventing Cardiotoxicity in Patients with Cancer Undergoing Chemotherapy.神经激素疗法在预防接受化疗的癌症患者心脏毒性方面的疗效。

JACC CardioOncol. 2019 Sep;1(1):54-65. doi: 10.1016/j.jaccao.2019.08.006. Epub 2019 Sep 24.

Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia.癌症治疗的心脏不良影响：心脏毒性和心律失常。

Nat Rev Cardiol. 2020 Aug;17(8):474-502. doi: 10.1038/s41569-020-0348-1. Epub 2020 Mar 30.

Mechanisms of Anthracycline-Induced Cardiotoxicity: Is Mitochondrial Dysfunction the Answer?蒽环类药物所致心脏毒性的机制：线粒体功能障碍是答案吗？

Front Cardiovasc Med. 2020 Mar 12;7:35. doi: 10.3389/fcvm.2020.00035. eCollection 2020.

Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies).依那普利和卡维地洛预防恶性血液病患者化疗引起的左心室收缩功能障碍：OVERCOME 试验（依那普利和卡维地洛预防接受强化化疗治疗恶性血液病患者左心室功能障碍）。

J Am Coll Cardiol. 2013 Jun 11;61(23):2355-62. doi: 10.1016/j.jacc.2013.02.072. Epub 2013 Apr 10.

Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study.比索洛尔对蒽环类药物诱导性心肌病的保护作用：一项随机对照研究。

Int J Cardiol. 2013 Sep 1;167(5):2306-10. doi: 10.1016/j.ijcard.2012.06.023. Epub 2012 Jun 22.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Cardioprotection with nebivolol in patients undergoing anthracyclines: a randomized placebo-controlled trial.

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

本文引用的文献